Table 2. Patient and tumour characteristics of cell cycle checkpoint kinase 2 (CHEK2) 1100delC mutation carriers and noncarriers.
|
Carrier |
Noncarrier |
|
|||
|---|---|---|---|---|---|
| n | % | n | % | P-value | |
| Number of patients |
193 |
|
4529 |
|
|
| Median follow-up in years |
6.8 (0.6–31.9) |
|
7.2 (0.1–38.9) |
|
|
|
Age at breast cancer diagnosis | |||||
| Median (years) | 50.0 | 51.4 | 0.003 | ||
| Mean (years) | 50.1 | 52.8 | |||
| Range (years) | 22.5–78.0 | 18.7–79.9 | |||
| <40 | 37 | 19.2 | 714 | 15.8 | 0.14 |
| 40–50 | 59 | 30.6 | 1326 | 29.3 | |
| ⩾50 |
97 |
50.3 |
2489 |
55.0 |
|
|
Year of diagnosis | |||||
| <1990 | 58 | 30.1 | 1590 | 35.1 | 0.04 |
| 1990–2000 | 83 | 43.0 | 1996 | 44.1 | |
| >2000 |
52 |
26.9 |
943 |
20.8 |
|
|
Synchronous contralateral breast cancer | |||||
| No | 189 | 97.9 | 4443 | 98.1 | 0.87 |
| Yes |
4 |
2.1 |
86 |
1.9 |
|
|
T stage | |||||
| T1 | 95 | 51.9 | 2074 | 47.2 | 0.23 |
| T2 | 72 | 39.3 | 1886 | 42.9 | |
| T3 | 11 | 6.0 | 264 | 6.0 | |
| T4 | 5 | 2.7 | 168 | 3.8 | |
| Unknown |
10 |
(5.2) |
137 |
(3.0) |
|
|
N stage | |||||
| Negative | 105 | 57.1 | 2388 | 53.9 | 0.31 |
| 1–3 | 35 | 19.0 | 1096 | 24.7 | |
| 4+ | 44 | 23.9 | 949 | 21.4 | |
| Unknown |
9 |
(4.7) |
96 |
(2.1) |
|
|
Differentiation grade | |||||
| 1 | 21 | 14.7 | 370 | 10.5 | 0.11 |
| 2 | 52 | 36.4 | 1155 | 32.6 | |
| 3 | 70 | 49.0 | 2014 | 56.9 | |
| Unknown |
50 |
(25.9) |
990 |
(21.9) |
|
|
Hormone receptor status | |||||
| Negative | 9 | 5.5 | 759 | 19.3 | <0.001 |
| Positive | 157 | 94.5 | 3173 | 80.7 | |
| Unknown |
30 |
(15.5) |
597 |
(13.2) |
|
|
HER2/neu | |||||
| Negative | 73 | 76.0 | 1886 | 80.7 | 0.26 |
| Positive | 23 | 24.0 | 452 | 19.3 | |
| Unknown | 97 | (50.2) | 2191 | (48.3) | |